Triple-drug attack aims to wipe out hidden leukemia cells
NCT ID NCT07690891
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of three drugs—nemtabrutinib, venetoclax, and obinutuzumab—as a first treatment for people with chronic lymphocytic leukemia (CLL). The goal is to see if this cocktail can reduce the disease to undetectable levels in the bone marrow and blood. Participants receive the drugs over 15 cycles, with the venetoclax and obinutuzumab added later in the schedule. The study enrolls adults who meet standard criteria to start treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nemtabrutinib, venetoclax, and obinutuzumab
- What this could lead to
- If successful, this combination could become a new first-line treatment option for chronic lymphocytic leukemia, potentially achieving deep remission with undetectable disease levels.
- What could go wrong
- This is an early phase 2 study with only 30 participants, so results may not apply broadly. The three-drug combination may cause side effects like low blood counts or infusion reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Smartwatches track hidden heart risk in blood cancer patients
- Engineered immune cells take aim at stubborn blood cancers
- Can a tailored exercise and diet plan beat cancer fatigue?
- Triple-Drug cocktail aims to tame untreated CLL
- New combo aims to put CLL into deep remission and let patients stop treatment